Clinical trials based on this preclinical research eventually led to the U.S. Food and Drug Administration approval of the FTI lonafarnib (brand name Zokinvy) for HGPS, MAD-B, and related progeroid syndromes with accumulation of prelamin A variants [46–48]. Here, LMNA is linked to progeroid syndrome.